The changing states of T cell populations responsible for the chronic course of allergic inflammation and diseases, including allergic bronchial asthma, are not yet sufficiently characterized. The aim of this study was to detect phenotypic changes in the CD45RA/CD45RO positive T lymphocytes and the level of regulatory cytokines (TNFα, IFNγ, IL-4, IL-6, IL-8, IL-10, IL-13, IL-17А, IL-17F) in allergic respiratory diseases (ARD) in children. In blood of 90 children aged 3-11 (60 children with ARD and 30 healthy peers) were studied of the immune cellular populations and cytokine indices. The levels of IL-4, IL-8, IL-10, IL-13, IL-17A and IL-17F in blood serum of children with bronchial asthma and allergic rhinitis differed from appropriate indices in control group (p = 0.001). The quantity of CD3+CD8+CD45RACD45RO+ cells, T helpers (p < 0.05) and Th effectors simultaneously expressing both isoforms of the CD45RA+ and CD45RO receptor in peripheral blood of children with ARD significantly exceeded those in control group (p < 0.001). In healthy children, Th17 population (CD3+CD4+CD196 lymphocytes) comprised 9.49±1.6% of CD3+CD4+ of cells, the number of such lymphocytes was significantly increased to 14.5±0.77 in children with allergic diseases (p < 0.001). Absolute numbers of Th17+ cells were 93.0±9.30 and 127,0±72.0 cells/µl respectively (p = 0.002). Indicators of CD4CD45RO positive memory cells in children with ARD was determined as significantly lower (p < 0.001), whereas quantity of CD3+CD19+ proved to be higher (p < 0.05) than in healthy peers. Absolute counts of these cells did not differ between the groups. The number of CD8+CD45RO+T lymphocytes was significantly higher in children with allergic diseases (p < 0.025). This research shows that the quantitative ratio of CD3+CD8+CD45RA+ and CD3+CD8+CD45RO+ populations of T cells, and increased levels of cytokines, synthesizable via Th2 and Th17, in peripheral blood may be helpful for understanding genesis of allergic respiratory diseases, and extends our knowledge on immune mechanisms of allergic disorders for individualization of therapeutic programs.
Background. Comparative study of clinical and immunological efficiency of systemic [with desloratadine (Aerius®, Bayer n=28)] and topical [with azelastin (Allergodil®, Meda Pharma) n=28] antihistamine single-agent treatment of persistent allergic rhinitis in primary school children (56 children from 6 to 11 years old) was carried out on the basis of monitoring the dynamics of nasal mucosa inflammatory biomarkers (IgE, sIgA, IL-4, IL-8, IL-13, IFN-y, TNFa). Materials and Methods. Questionnaires, selfmonitoring diaries with daily score-based assessment of the symptoms and the score of used pharmacologic agents, nasal discharge and touch smears of nasal cavity mucosa were used as investigative parameters in the study. The study was performed with the permission of the Biomedical Ethics Committee of the State Budgetary Educational Institution of Higher Professional Education «Pacific State Medical University» of the Ministry ofHealth of the Russian Federation. Results. A monthlong therapy with desloratadine enabled clinical control of the symptoms of mild and moderate persistent allergic rhinitis in primary school children in 92,8% of cases and allowed to stop local allergic inflammation intensity as was proved by increasing symptom-free number of days and the fact that symptomatic treatment was not required. The use of desloratadine in the course of the next three months ensured retention of the achieved control. Side and adverse effects in the given group were not registered.
Introduction. The study of genes that control the activity of cytokines is one of the important issues in revealing the pathogenetic mechanisms of allergic diseases. Aims. Determination of the frequency of occurrence of polymorphic gene markers genotypes and characterization of the interleukins 17A, 17F content in blood serum in children with bronchial asthma and allergic rhinitis. Materials and methods. A comprehensive survey of 110 children with allergic diseases of 311 years old and 60 healthy peers. The material for genetic analysis was DNA with the study of mutation points of IL-17A at position 197 (GA) and IL-17F 7488 (TC). The content of IL-17A, IL-17F interleukins was measured by enzymelinked assay. For the statistical analysis we used the Statistica 10, methods for comparing unrelated groups of genotypes distributions to expected values at HardyWeinberg equilibrium with 2. Results. The frequency of occurrence of genotypes in a group of healthy children was as follows: IL-17A (G197A) heterozygous GA (63,333%), homozygous GG (36,667%); IL-17F (T7488C) TT (36,667%), CT (63,333%), genotypes AA and CC werent determined. In children with allergic diseases, all genotypes were determined: IL-17A (G197A), GG (11,818%), AA (19,091%) and GA (69,091%), IL-17F (T7488C), TT (5,454%), CC (35,455%) and CT (59,091%) with the highest specific gravity of the GG genotype and TT. There were no significant differences in IL-17A, IL-17F levels in the blood serum depending on the genotype. Discussion. There were significant differences in the structure of the polymorphisms of the IL-17A, IL-17F genes, blood levels of IL-17A, IL-17F and the risk of the disease in allergic children and healthy peers. The frequency of allergic diseases in children with genotypes AA and TT is statistically higher, but with genotypes GG, CC is statistically lower than with other genotypes.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.